Imagine trying to drain a flooded basement without knowing exactly where the water is trapped; that is how doctors currently treat fluid buildup in heart failure. This project creates a smart test that finds specific biological markers in the blood to tell doctors exactly how much fluid is there. It then uses AI to suggest the perfect dose of medication for each individual patient.
Diuretic therapy for heart failure is currently empirical and inaccurate, leading to high hospital readmission rates. Up to 70% of patients remain congested despite treatment, increasing mortality and healthcare costs.
A retrospective study platform integrating clinical and biomarker data, and a list of 10 candidate molecules for congestion assessment.
If you are a diagnostic company dealing with the lack of rapid tests for heart congestion — this project developed a Point of Care companion diagnostic that allows for immediate biomarker assessment. This enables the creation of a new product line for bedside heart failure management.
If you are a software firm dealing with generic treatment guidelines that fail 70% of patients — this project developed an AI-based multiparametric score that predicts congestion and prognosis. This can be integrated into hospital software to personalize diuretic dosing.
If you are a pharma company dealing with poor patient adherence to disease-modifying therapies due to inefficient diuretic use — this project developed a biomarker-based toolkit that optimizes fluid management. This ensures patients are stable enough to tolerate and adhere to long-term medications.
Based on available project data, the specific unit price or cost of the toolkit is not mentioned; only the total EU contribution of EUR 9,600,663 for development is provided.
The project includes a specific objective to set up a Strategy plan for industrial development and market access of the companion diagnostic.
Based on available project data, the specific licensing terms are not listed, but the project aims to provide a foundation for regulatory agencies and scientific societies to disseminate recommendations.
The project period runs from 2023-10-01 to 2028-09-30, suggesting the toolkit will be refined through 2028.
It integrates via a Point of Care companion diagnostic and a decision-making tool designed to replace empirical diuretic dosing with biomarker-driven precision.
The consortium is highly diversified with 25 partners across 11 countries, showing strong European reach. While dominated by academic and research entities (16 combined), there is a 12% industry participation rate with 3 companies, including 3 SMEs, indicating a clear intent to move from lab to market.
Contact IRCCS AZIENDA OSPEDALIERO- UNIVERSITARIA DI BOLOGNA
Contact us to identify potential licensing opportunities for the AI-score or PoC diagnostic.
